The U.S. Food and Drug Administration has approved mFLUSIVA, Moderna’s mRNA-based seasonal influenza vaccine, marking the first time messenger RNA technology has been cleared for flu prevention in the United States. The approval, announced in August 2026, opens a new chapter for a vaccine platform that reshaped public health during the COVID-19 pandemic.
The vaccine is authorized for adults ages 50 and older, with accelerated approval extending to adults 65 and above based on immune response data. It is expected to be available for the 2026–2027 respiratory virus season.
What Is mFLUSIVA?
mFLUSIVA (formerly known as mRNA-1010) is a quadrivalent influenza vaccine that uses messenger RNA to instruct human cells to produce a harmless piece of the flu virus’s surface protein. The immune system then recognizes this protein and builds antibodies ready to respond if a real infection occurs.
Unlike the mRNA COVID-19 vaccines that many are already familiar with, mFLUSIVA targets four influenza strains selected each year by global surveillance networks coordinated by the World Health Organization.
How mRNA Flu Vaccines Differ From Traditional Shots
Most seasonal flu vaccines in circulation today are produced by growing virus in chicken eggs—a process refined over more than 70 years. It is reliable, but it is also slow: manufacturers typically need at least six months from the moment strain recommendations are issued to the moment doses ship.
That timeline creates a public health vulnerability. If a circulating strain drifts or shifts after production begins, the finished vaccine can be a poor match by the time flu season arrives. The 2014–2015 season, when the H3N2 strain evolved after manufacturing, is a textbook example: CDC estimates pegged effectiveness that year at just 19%.
mRNA platforms flip that equation. Because the vaccine is essentially a genetic script rather than a cultured virus, developers can theoretically redesign and manufacture updated doses within weeks. That flexibility is a big part of why regulators and epidemiologists have watched mRNA flu candidates so closely.
Egg-Free Production
mFLUSIVA is also produced without eggs, which may benefit people with severe egg allergies. Traditional flu shots have long been considered safe for most people with egg sensitivity, but egg-free options have historically been limited.
What the Clinical Trials Showed
Moderna’s approval was supported by two pivotal studies. The larger Phase 3 trial enrolled more than 40,000 adults ages 50 and older across multiple countries. According to the company’s published results, mFLUSIVA demonstrated approximately 27% greater relative vaccine efficacy against laboratory-confirmed influenza compared with a standard-dose licensed flu vaccine.
A second study of about 2,900 U.S. adults ages 65 and older focused on immune response, evaluating how well the vaccine triggered antibody production in a higher-risk age group. That trial supported the accelerated approval pathway for the 65-plus population, though the FDA has noted that confirmatory clinical-outcome data will still be required.
“This is an important addition to our influenza prevention toolkit,” said Dr. Dung Trinh of MemorialCare in an interview with Medical News Today. Other specialists have offered a more measured take. Dr. David Cutler of Providence Saint John’s Health Center called the accelerated approval for the 65-plus group “cautiously favorable,” emphasizing that additional real-world outcome data will help clarify long-term benefits.
Who Might Benefit Most
Adults 50 and older bear a disproportionate share of the flu’s burden. The CDC estimates that people 65 and older account for the majority of seasonal flu hospitalizations and deaths in a typical year. Standard-dose flu vaccines can lose effectiveness in older adults because immune systems tend to respond less robustly with age, which is why high-dose and adjuvanted options have been developed specifically for seniors.
If mFLUSIVA’s 27% relative-efficacy edge over standard-dose shots holds up in real-world use, it could meaningfully reduce infections, hospitalizations, and complications for a population that consistently struggles with flu-related illness.
Side Effects to Expect
Reactions reported in trials were broadly similar to those seen with mRNA COVID-19 vaccines and included:
- Injection site pain, redness, or swelling
- Headache and fatigue
- Muscle or joint aches
- Nausea, vomiting, or chills
- Low-grade fever
Rare severe allergic reactions can occur with any vaccine, which is why administration typically happens in a setting where post-shot observation is possible. Anyone with a history of severe reaction to a previous flu shot or vaccine ingredient should discuss options with a healthcare provider.
When It Will Be Available
Moderna has indicated that mFLUSIVA is expected to reach U.S. pharmacies and clinics for the 2026–2027 flu season. Timing of insurance coverage, CDC advisory committee recommendations, and pharmacy stocking will shape how easily patients can access it. Public health officials generally recommend getting a flu shot by the end of October to build immunity before peak season, which historically runs from December through February.
A Broader Shift in Vaccine Science
The approval of mFLUSIVA underscores how mRNA has evolved from a pandemic response tool into a versatile platform. Research pipelines now include mRNA-based candidates for respiratory syncytial virus (RSV), cytomegalovirus, certain cancers, and combination shots that could someday cover flu and COVID-19 in a single dose.
Whether mRNA becomes the dominant flu vaccine format will depend on real-world performance, cost, and public acceptance. But for the first time, the annual flu shot conversation includes an option built on a fundamentally different biological platform than the one used since the 1940s.
Talking to Your Healthcare Provider
Choosing among flu vaccine options—standard-dose, high-dose, adjuvanted, recombinant, and now mRNA—can be confusing. Factors that may influence the decision include age, existing health conditions, allergy history, and local availability. A primary care physician or pharmacist can help weigh the tradeoffs based on individual circumstances.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.